These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 36414028)

  • 21. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response.
    Andrieu GP; Shafran JS; Smith CL; Belkina AC; Casey AN; Jafari N; Denis GV
    Cancer Lett; 2019 Nov; 465():45-58. PubMed ID: 31473251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
    Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
    Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines.
    Bräutigam K; Kabore-Wolff E; Hussain AF; Polack S; Rody A; Hanker L; Köster F
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2923-2933. PubMed ID: 34185141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclin-dependent kinase inhibitors enhance programmed cell death protein 1 immune checkpoint blockade efficacy in triple-negative breast cancer by affecting the immune microenvironment.
    Wu J; Wang W; Gao L; Shao X; Wang X
    Cancer; 2024 Apr; 130(S8):1449-1463. PubMed ID: 38482921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STAT3 and PD-L1 are negatively correlated with ATM and have impact on the prognosis of triple-negative breast cancer patients with low ATM expression.
    Song YM; Qian XL; Xia XQ; Li YQ; Sun YY; Jia YM; Wang J; Xue HQ; Gao GS; Wang XZ; Zhang XM; Guo XJ
    Breast Cancer Res Treat; 2022 Nov; 196(1):45-56. PubMed ID: 36056297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1.
    Zhang R; Yang Y; Dong W; Lin M; He J; Zhang X; Tian T; Yang Y; Chen K; Lei QY; Zhang S; Xu Y; Lv L
    Proc Natl Acad Sci U S A; 2022 Feb; 119(8):. PubMed ID: 35181605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1/PD-L1 blockade inhibits epithelial-mesenchymal transition and improves chemotherapeutic response in breast cancer.
    Antony GR; Littleflower AB; Parambil ST; Subhadradevi L
    Med Oncol; 2023 Feb; 40(4):108. PubMed ID: 36842157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer.
    Thongchot S; Jirapongwattana N; Luangwattananun P; Chiraphapphaiboon W; Chuangchot N; Sa-Nguanraksa D; O-Charoenrat P; Thuwajit P; Yenchitsomanus PT; Thuwajit C
    Mol Cancer Ther; 2022 May; 21(5):727-739. PubMed ID: 35313339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Saccharide analog, 2-deoxy-d-glucose enhances 4-1BB-mediated antitumor immunity via PD-L1 deglycosylation.
    Kim B; Sun R; Oh W; Kim AMJ; Schwarz JR; Lim SO
    Mol Carcinog; 2020 Jul; 59(7):691-700. PubMed ID: 32115801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of programmed death ligand 1 (PD-L1) expression in breast cancer cells by sesamin.
    Kongtawelert P; Wudtiwai B; Shwe TH; Pothacharoen P; Phitak T
    Int Immunopharmacol; 2020 Sep; 86():106759. PubMed ID: 32663768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
    Chen XY; Li B; Wang Y; Jin J; Yang Y; Huang LH; Yang MD; Zhang J; Wang BY; Shao ZM; Ni T; Huang SL; Hu XC; Tao ZH
    Cancer Commun (Lond); 2023 Sep; 43(9):1003-1026. PubMed ID: 37434394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1
    Li X; Du H; Zhan S; Liu W; Wang Z; Lan J; PuYang L; Wan Y; Qu Q; Wang S; Yang Y; Wang Q; Xie F
    Front Immunol; 2022; 13():830606. PubMed ID: 35935985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652.
    Liu Y; Peng Y; Du W; Yu C; Peng Z; Qin L; Ma Y; Wu X; Peng Y; Cheng X; Xia L; Fa H; Wu Y; Sun L; Liu J; Liu Z; Shang Y; Wang S; Liang J
    Cell Rep; 2023 Nov; 42(11):113343. PubMed ID: 37906592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1.
    Zhang M; Wang N; Song P; Fu Y; Ren Y; Li Z; Wang J
    Cell Prolif; 2020 Sep; 53(9):e12855. PubMed ID: 32687248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of programmed death ligand 1 (PD-L1) expression by TNF-related apoptosis-inducing ligand (TRAIL) in triple-negative breast cancer cells.
    Pimentel JM; Zhou JY; Wu GS
    Mol Carcinog; 2023 Feb; 62(2):135-144. PubMed ID: 36239572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
    Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
    Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.